✦ LIBER ✦

An open-label safety and efficacy study of an anti-CD20 antibody (rituximab, Rituxan) for anti-B-cell therapy in the treatment of systemic lupus erythematosus

✍ Scribed by RA Eisenberg, S Khan, J Stansberry, D Tsai, S Kolasinski, E Rieder…

Book ID: 120707235
Publisher: BioMed Central
Year: 2004
Tongue: English
Weight: 391 KB
Volume: 6
Category: Article
ISSN: 1478-6354
DOI: 10.1186/ar1407

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase I trial of B-cell depletion with

A Phase I trial of B-cell depletion with anti-CD20 monoclonal antibody (rituximab) in the treatment of systemic lupus erythematosus

✍ R Eisenberg, D Albert, J Stansberry, D Tsai, S Kolasinski, S Khan 📂 Article 📅 2003 🏛 BioMed Central 🌐 English ⚖ 554 KB

Safety and efficacy of tumor necrosis fa

Safety and efficacy of tumor necrosis factor α blockade in systemic lupus erythematosus: An open-label study

✍ Martin Aringer; Winfried B. Graninger; Günter Steiner; Josef S. Smolen 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 116 KB 👁 1 views

## Abstract ## Objective To investigate the safety of therapeutic tumor necrosis factor α (TNFα) blockade in patients with systemic lupus erythematosus (SLE), in whom this proinflammatory cytokine is significantly increased and may be involved in the disease pathogenesis. ## Methods In an open‐l

Efficacy and safety of adalimumab when a

Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study

✍ K. Papp; V. Ho; H.D. Teixeira; B. Guerette; K. Chen; C. Lynde 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB

Immunotherapy with FBTA05 (Bi20), a trif

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

✍ Raymund Buhmann, Stanglmaier Michael, Hess Juergen… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 328 KB

An open-label pilot study of the effecti

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

✍ Arie E. van der Bijl; Ferdinand C. Breedveld; Christian E. Antoni; Joachim R. Ka 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 182 KB